Gene expression profiles in clinically T1-2N0 ER+HER2 − breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed
ConclusionIf no SLNB is performed, clinical risk status according to the guideline of 2020 and PREDICT predicts a very low risk for systemic undertreatment. The number of GEPs needed to identify one patient at risk for undertreatment does not justify its standard use.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Breast Conservation Surgery | Cancer | Cancer & Oncology | Chemotherapy | Genetics | HER2 | Netherlands Health | Study